These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

86 related articles for article (PubMed ID: 8260254)

  • 1. Cisplatin and continuous infusion vindesine and 5-fluorouracil in non-small cell lung cancer (NSCLC) (ATTIT 002). ATTIT (Association pour le Traitment des Tumeurs Intra-Thoraciques).
    Riggi M; Cvitkovic E; de Cremoux H; Ruffie P; Monnet I; Voisin S; Villalobos W; Azli N; Saltiel JC
    Eur J Cancer; 1993; 29A(13):1914-5. PubMed ID: 8260254
    [No Abstract]   [Full Text] [Related]  

  • 2. Influence of pretreatment clinical characteristics on the response rate to mitomycin/vindesine/cisplatin (MVP) in unresectable non-small cell lung cancer. ATTIT (Association pour le Traitement des Tumeurs Intra-Thoraciques).
    Riggi M; Ruffie P; Voisin S; Monnet I; de Cremoux H; Saltiel JC; Martin M; Vergne L; Huet J; Cvitkovic E
    Eur J Cancer; 1991; 27(10):1238-42. PubMed ID: 1659842
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cisplatin-based chemotherapy for postoperative recurrence in non-small cell lung cancer patients: relation of the in vitro chemosensitive test to clinical response.
    Higashiyama M; Kodama K; Yokouchi H; Takami K; Nakagawa H; Imamura F; Minamigawa K; Kobayashi H
    Oncol Rep; 2001; 8(2):279-83. PubMed ID: 11182040
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Pilot study of a continuous five-day intravenous infusion of cisplatin plus vindesine in advanced non-small cell lung cancer].
    Mori K; Saito Y; Yokoi K; Tominaga K; Miyazawa N
    Gan To Kagaku Ryoho; 1989 Jul; 16(7):2465-8. PubMed ID: 2546506
    [No Abstract]   [Full Text] [Related]  

  • 5. Bolus versus 5-day continuous infusion of cisplatin with mitomycin and vindesine in the treatment of advanced non-small cell lung cancer (NSCLC): a phase III prospective randomised trial of the Italian Oncology Group for Clinical Research (GOIRC).
    Boni C; Savoldi L; Bisagni G; Ceci G; Crinò L; De Lisi V; Di Costanzo F; Lasagni L; Manenti AL; Moretti G; Rondini E; Sassi M; Zadro A
    Eur J Cancer; 1998 Nov; 34(12):1974-6. PubMed ID: 10023325
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Effect of the pulmonary artery infusion chemotherapy of non-small cel lung cancer].
    Fukuhara H; Oomura M; Sasaki H
    Gan To Kagaku Ryoho; 1989 Jul; 16(7):2469-72. PubMed ID: 2546507
    [No Abstract]   [Full Text] [Related]  

  • 7. Cisplatin-mitomycin and vindesine in the treatment of inoperable non-small cell lung cancer groupe français de pneumo-cancérologie (GFPC).
    Thomas P; Kleisbauer JP; Perol M; Taytard A; Poirier R; Le Caer H; Guerin JC; Bonnaud F; Balmes P; Carles P
    Eur J Cancer; 1993; 29A(3):477. PubMed ID: 8398353
    [No Abstract]   [Full Text] [Related]  

  • 8. Phase II study of oxaliplatin in poor-prognosis non-small cell lung cancer (NSCLC). ATTIT. Association pour le Traitement des Tumeurs Intra Thoraciques.
    Monnet I; Brienza S; Hugret F; Voisin S; Gastiaburu J; Saltiel JC; Soulié P; Armand JP; Cvitkovic E; de Cremoux H
    Eur J Cancer; 1998 Jun; 34(7):1124-7. PubMed ID: 9849465
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Combined chemotherapy and differentiation therapy in the treatment of advanced non-small-cell lung cancer.
    Recchia F; Sica G; De Filippis S; Rea S; Frati L
    Anticancer Res; 1997; 17(5B):3761-5. PubMed ID: 9427776
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A three-arm trial of vinorelbine (Navelbine) plus cisplatin, vindesine plus cisplatin, and single-agent vinorelbine in the treatment of non-small cell lung cancer: an expanded analysis.
    Le Chevalier T; Pujol JL; Douillard JY; Alberola V; Monnier A; Riviere A; Lianes P; Chomy P; Cigolari S; Besson F
    Semin Oncol; 1994 Oct; 21(5 Suppl 10):28-33; discussion 33-4. PubMed ID: 7973766
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Induction chemotherapy with cisplatin, etoposide and vindesine before radiation therapy for nonsmall-cell lung cancer. A randomized study.
    Van Houtte P; Klastersky J; Renaud A; Michel J; Vandermoten G; Nguyen H; Sculier JP; Devriendt J; Mommen P
    Antibiot Chemother (1971); 1988; 41():131-7. PubMed ID: 2854432
    [No Abstract]   [Full Text] [Related]  

  • 12. The role of three cisplatin-based chemotherapy regimens in the treatment of advanced non-small cell lung cancer.
    Jirillo A; Pavanato G; Lonardi F; Bonciarelli G; Balli M
    Eur J Cancer; 1992; 28A(12):2086. PubMed ID: 1384609
    [No Abstract]   [Full Text] [Related]  

  • 13. Chemotherapy for non-small cell lung cancer: a randomized trial of cisplatin/vindesine v no chemotherapy.
    Williams CJ; Woods R; Levi J; Page J
    Semin Oncol; 1988 Dec; 15(6 Suppl 7):58-61. PubMed ID: 2851181
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A phase II study of cisplatin, vindesine and continuously infused 5-fluorouracil in the treatment of advanced non-small-cell lung cancer. Osaka Lung Cancer Chemotherapy Study Group.
    Nakano T; Ikegami H; Nakamura S; Kawase T; Nishikawa H; Yokota S; Yoshida M; Tachibana T; Igarashi T; Komuta K; Higashino K
    Br J Cancer; 1996 May; 73(9):1096-100. PubMed ID: 8624270
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cis-platin, vindesine, doxorubicin and cyclophosphamide in the treatment of non-small cell bronchogenic carcinoma.
    Athanassiades P; Lagoudis M; Kostis E
    J Chemother; 1989 Jul; 1(4 Suppl):1205-6. PubMed ID: 16312835
    [No Abstract]   [Full Text] [Related]  

  • 16. Cisplatin, vindesine, mitomycin-C and 13-cis retinoic acid in the treatment of advanced non small cell lung cancer. A phase II pilot study.
    Recchia F; Sica G; De Filippis S; Rosselli M; Saggio G; Guerriero G; Pompili P; Rea S
    Anticancer Res; 2000; 20(3B):1985-90. PubMed ID: 10928138
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase III randomized trial of docetaxel plus cisplatin versus vindesine plus cisplatin in patients with stage IV non-small-cell lung cancer: the Japanese Taxotere Lung Cancer Study Group.
    Kubota K; Watanabe K; Kunitoh H; Noda K; Ichinose Y; Katakami N; Sugiura T; Kawahara M; Yokoyama A; Yokota S; Yoneda S; Matsui K; Kudo S; Shibuya M; Isobe T; Segawa Y; Nishiwaki Y; Ohashi Y; Niitani H;
    J Clin Oncol; 2004 Jan; 22(2):254-61. PubMed ID: 14722033
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Establishment of the standard regimen for non-small-cell lung cancer in Japan.
    Masuda N
    Oncology (Williston Park); 2001 Jan; 15(1 Suppl 1):13-8. PubMed ID: 11221016
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A randomised clinical trial of vindesine plus cisplatin versus mitomycin plus vindesine and cisplatin in advanced non-small cell lung cancer.
    Shinkai T; Eguchi K; Sasaki Y; Tamura T; Ohe Y; Kojima A; Oshita F; Saijo N
    Eur J Cancer; 1991; 27(5):571-5. PubMed ID: 1647183
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [A randomized trial comparing vindesine plus cisplatin with mitomycin C, vindesine plus cisplatin in patients with advanced non-small cell lung cancer].
    Fujii M; Kiura K; Okabe K; Toki H; Kimura M
    Gan To Kagaku Ryoho; 1987 Sep; 14(9):2676-81. PubMed ID: 2820312
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.